公开(公告)号：EP4000609B1

公开(公告)日：2024-11-13

申请号：EP20841290.8

申请日：2020-07-13

发明人： LEE, Tae Hoon ,  LEE, Sun Woo ,  CHO, Eun Jin ,  MIN, Sang Hyun ,  CHOI, Dong Kyu ,  KIM, Geun Joong

IPC分类号： A61K31/18 ,  A61P19/00 ,  A61P19/10 ,  A61P19/02 ,  A23L33/10

公开(公告)号：EP4458412A1

公开(公告)日：2024-11-06

申请号：EP23171966.7

申请日：2023-05-05

申请人： University College Cardiff Consultants, Ltd. ,  University of Birmingham

发明人： MEHELLOU, Youcef ,  WILLCOX, Benjamin

IPC分类号： A61P19/00 ,  A61P35/00 ,  A61P37/00 ,  C07F9/44

摘要： The invention relates to a novel phosphoantigen (PAg) prodrug compound which provides for a potent activation of therapeutically active γδ T cells. The PAg prodrug compound of the invention can be used for the preparation of therapeutically active γδ T cells as well as in the immunotherapy of different diseases, and in particular different types of cancer. The invention further relates to a method for expanding γδ T-cells ex vivo which makes use of the PAg prodrug compound of the invention. Also provided are γδ T-cells which have been expanded with the PAg prodrug compound of the invention and pharmaceutical compositions comprising such expanded cells and/or the PAg prodrug compound of the invention.

公开(公告)号：EP4458347A1

公开(公告)日：2024-11-06

申请号：EP23743429.5

申请日：2023-01-16

申请人： LG Chem, Ltd.

发明人： BAEK, Jaeuk ,  KIM, Sung Won ,  YOON, Jung Woon

IPC分类号： A61K9/00 ,  A61K47/02 ,  A61K47/26 ,  A61K31/4725 ,  A61K31/422 ,  A61P19/00

摘要： The present invention relates to an injectable formulation containing, as an active pharmaceutical ingredient (API), an isoxazoline derivative or pharmaceutically acceptable salt thereof useful as a caspase inhibitor. The injectable formulation according to the present invention includes a first agent composed of a high dose of the API, and a second agent that is a solvent capable of dissolving the first agent, and may be prepared by mixing the first agent and the second agent immediately before administration. The injectable formulation stably contains the active API and thus has the advantage that effective drug efficacy can be expected when administered to a patient.

公开(公告)号：EP4161927B9

公开(公告)日：2024-11-06

申请号：EP21732126.4

申请日：2021-06-07

发明人： BUTLER, Christopher Ryan ,  GARNSEY, Michelle Renee ,  OGILVIE, Kevin Alexander ,  POLIVKOVA, Jana ,  SAMMONS, Matthew Forrest ,  SMITH, Aaron Christopher ,  YANG, Qingyi

IPC分类号： C07D471/20 ,  C07D519/00 ,  A61K31/438 ,  A61P1/08 ,  A61P3/04 ,  A61P19/00 ,  A61P21/00 ,  A61P29/00

公开(公告)号：EP4011363B1

公开(公告)日：2024-10-30

申请号：EP21213679.0

申请日：2009-09-25

发明人： MURPHY, William ,  JONGPAIBOONKIT, Leenaporn

IPC分类号： A61K9/14 ,  A61K35/00 ,  A61K9/50 ,  A61K31/19 ,  A61P19/00 ,  C12N15/87 ,  A61K35/02

公开(公告)号：EP3815715B1

公开(公告)日：2024-09-11

申请号：EP19825285.0

申请日：2019-06-28

IPC分类号： C12N15/115 ,  A61K9/08 ,  A61K48/00 ,  A61K31/7105 ,  A61K47/26 ,  A61P9/00 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/04 ,  A61P27/02 ,  A61P29/00

CPC分类号： A61K9/08 ,  A61K31/7105 ,  A61K47/26 ,  A61P9/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/04 ,  A61P19/00 ,  A61P27/02 ,  A61P29/00 ,  C12N15/115 ,  C12N2310/1620130101 ,  C12N2310/351520130101 ,  A61K9/0019 ,  C12N2320/5020130101 ,  C12N2310/34420130101

公开(公告)号：EP4408458A1

公开(公告)日：2024-08-07

申请号：EP22800123.6

申请日：2022-09-29

申请人： Jennissen, Herbert

发明人： Jennissen, Herbert

IPC分类号： A61K38/18 ,  A61L27/22 ,  A61L27/36 ,  A61L27/56 ,  A61P19/00 ,  C07K14/51 ,  A61L27/58 ,  A61L31/14 ,  C12N5/077

CPC分类号： A61K38/1875 ,  C07K14/51 ,  A61L27/227 ,  A61P19/00 ,  A61L27/365 ,  A61L27/56 ,  A61L27/58 ,  A61L31/148 ,  C12N5/0654

公开(公告)号：EP4406563A1

公开(公告)日：2024-07-31

申请号：EP21958116.2

申请日：2021-10-20

申请人： Beijing Biosis Healing Biological Technology Co., Ltd.

发明人： ZHAO, Bo ,  WANG, Huasheng ,  WEI, Pengfei ,  JING, Wei ,  LIU, Zihao

IPC分类号： A61L27/36 ,  C07K19/00 ,  A61K9/133 ,  A61P19/00

CPC分类号： A61K9/127 ,  A61L27/22 ,  A61L27/36 ,  A61L27/38 ,  A61L27/50 ,  A61P19/00 ,  C07K19/00

摘要： The present disclosure relates a modified SIS membrane for tissue repair, a preparation method therefor and a use thereof. Specifically provided are a composition comprising a fusion polypeptide-modified SIS membrane and an extracellular vesicle, as well as a preparation method for and a use of the composition. It is proved that the fusion polypeptide-mediated SIS membrane and the composition containing the SIS membrane and the extracellular vesicle have excellent biological functions, and provide a broad prospect for treating bone defects or facilitating tissue healing or bone regeneration.

公开(公告)号：EP4368194A3

公开(公告)日：2024-07-31

申请号：EP24150415.8

申请日：2014-06-27

申请人： Bioverativ Therapeutics Inc.

发明人： CHHABRA, Ekta Seth ,  KULMAN, John ,  LIU, Tongyao

IPC分类号： A61P1/00 ,  C07K14/755 ,  A61P1/02 ,  A61P7/04 ,  A61P17/02 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P25/00 ,  A61K38/00

CPC分类号： A61K38/00 ,  C07K2319/0020130101 ,  C07K2319/5020130101 ,  C07K14/755 ,  A61P1/00 ,  A61P1/02 ,  A61P17/02 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P25/00 ,  A61P7/04

摘要： The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.

公开(公告)号：EP3116521B1

公开(公告)日：2024-07-31

申请号：EP15762288.7

申请日：2015-03-13

IPC分类号： A61K38/18 ,  A61K38/39 ,  A61K38/00 ,  A61L27/52 ,  A61L27/54 ,  A61L27/24 ,  A61L27/58 ,  A61L27/22 ,  A61L27/56 ,  A61P19/00

CPC分类号： A61L2400/0620130101 ,  A61L2400/1220130101 ,  A61K38/18 ,  A61K38/1875 ,  A61L27/222 ,  A61L27/24 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/2520130101 ,  A61L2300/25220130101 ,  A61K38/39 ,  A61P19/00